CTOs on the Move

Wabash County Hospital

www.wchospital.com

 
Wabash County Hospital is a county-owned, critical access hospital. With 25 inpatient beds, we offer critical care services, emergency services, cancer treatment and much more.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Shawnee Gardens

Shawnee Gardens Healthcare & Rehab Center is a healthcare facility that provides top quality medical care and skilled therapy in a newly renovated, state of the art facility.

Curio Wellness

Founded in 2014 in Baltimore, Maryland, Curio Wellness is a cGMP certified, vertically integrated medical cannabis company and trusted healthcare partner. Recognized as the leading wellness brand in cannabis by BDS Analytics, Curio is committed to serving patients with targeted, effective, and reliable cannabis-based medicine.

Empath Health

Empath Health is uniquely devoted to pioneering all-embracing care that provides for the full life. We`re here for all stages of care, for all dimensions of well-being and for all aspects dear to one`s life. We consider it a privilege and a calling to give more of ourselves in order to offer a truly exceptional experience, unlike any other.

Alliance Pharma

Alliance Pharma is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.